Zobrazeno 1 - 10
of 70
pro vyhledávání: '"M. Van Wagoner"'
Autor:
Amy Eichner, Laura A. Lewis, Bridget Leonard, Ryan M. Van Wagoner, Daniel Eichner, Matthew N. Fedoruk
Publikováno v:
Frontiers in Sports and Active Living, Vol 3 (2021)
This paper describes nine instances of positive anti-doping tests that could be accounted for by the use of permitted generic prescription drugs contaminated with diuretics, which are prohibited in sport at all times under the WADA Prohibited List. T
Externí odkaz:
https://doaj.org/article/4eef0f70092f49fe8daacc537daa353a
Autor:
Alberto Bosque, Kyle A. Nilson, Amanda B. Macedo, Adam M. Spivak, Nancie M. Archin, Ryan M. Van Wagoner, Laura J. Martins, Camille L. Novis, Matthew A. Szaniawski, Chris M. Ireland, David M. Margolis, David H. Price, Vicente Planelles
Publikováno v:
Cell Reports, Vol 18, Iss 5, Pp 1324-1334 (2017)
The presence of latent HIV-1 in infected individuals represents a major barrier preventing viral eradication. For that reason, reactivation of latent viruses in the presence of antiretroviral regimens has been proposed as a therapeutic strategy to ac
Externí odkaz:
https://doaj.org/article/92f594697d114cf5b8096f3da8d8641c
Autor:
Nader N. El-Chaar, Thomas E. Smith, Gajendra Shrestha, Stephen R. Piccolo, Mary Kay Harper, Ryan M. Van Wagoner, Zhenyu Lu, Ashlee R. Venancio, Chris M. Ireland, Andrea H. Bild, Philip J. Moos
Publikováno v:
Marine Drugs, Vol 19, Iss 1, p 41 (2021)
Patients diagnosed with basal-like breast cancer suffer from poor prognosis and limited treatment options. There is an urgent need to identify new targets that can benefit patients with basal-like and claudin-low (BL-CL) breast cancers. We screened f
Externí odkaz:
https://doaj.org/article/2081d053526c453998348719d335d5c2
Autor:
Jan Vicente, Allison K. Stewart, Ryan M. van Wagoner, Elizabeth Elliott, Andrea J. Bourdelais, Jeffrey L. C. Wright
Publikováno v:
Marine Drugs, Vol 13, Iss 8, Pp 4682-4700 (2015)
During an investigation of new actinomycete species from Caribbean sponges for novel bioactive natural products, frigocyclinone (1), dimethyldehydrorabelomycin (3) and six new angucyclinone derivatives were isolated from Streptomyces sp. strain M7_15
Externí odkaz:
https://doaj.org/article/b88f83fd39204b30b94f25982e2c0663
Autor:
Xiaomei Wei, Tim S. Bugni, Mary Kay Harper, Imelda T. Sandoval, Elizabeth J. Manos, Jennifer Swift, Ryan M. Van Wagoner, David A. Jones, Chris M. Ireland
Publikováno v:
Marine Drugs, Vol 8, Iss 6, Pp 1769-1778 (2010)
Three new minor components, the pyridoacridine alkaloids 1-hydroxy-deoxyamphimedine (1), 3-hydroxy-deoxyamphimedine (2), debromopetrosamine (3), and three known compounds, amphimedine (4), neoamphimedine (5) and deoxyamphimedine (6), have been isolat
Externí odkaz:
https://doaj.org/article/6da992cc4e684453bf5ea1b3b8317a76
Autor:
Daniel Eichner, Amy Eichner, Matthew Fedoruk, Laura A. Lewis, Bridget Leonard, Ryan M. Van Wagoner
Publikováno v:
Frontiers in Sports and Active Living
Frontiers in Sports and Active Living, Vol 3 (2021)
Frontiers in Sports and Active Living, Vol 3 (2021)
This paper describes nine instances of positive anti-doping tests that could be accounted for by the use of permitted generic prescription drugs contaminated with diuretics, which are prohibited in sport at all times under the WADA Prohibited List. T
Autor:
Carly M Van Wagoner, Fátima Rivera-Escalera, Laurey Dea Comeau, Casey Bauchle, Charles C. Chu, Clive Zent, Michael Rusty Elliott
Publikováno v:
The Journal of Immunology. 208:163.12-163.12
While monoclonal antibodies (mAb), such as αCD20, have significantly improved patient outcomes for B cell malignancies, patient responses vary and drug resistance can occur. One proposed limitation is the reduction of innate immune effector function
Autor:
Ashlee R. Venancio, Zhenyu Lu, Philip J. Moos, Thomas E Smith, Nader N. El-Chaar, Chris M. Ireland, Stephen R. Piccolo, Ryan M. Van Wagoner, Mary Kay Harper, Gajendra Shrestha, Andrea H. Bild
Publikováno v:
Marine Drugs, Vol 19, Iss 41, p 41 (2021)
Marine Drugs
Volume 19
Issue 1
Marine Drugs
Volume 19
Issue 1
Patients diagnosed with basal-like breast cancer suffer from poor prognosis and limited treatment options. There is an urgent need to identify new targets that can benefit patients with basal-like and claudin-low (BL-CL) breast cancers. We screened f
Autor:
Rhonda R. Roberts, Brian T. Luke, Carly M Van Wagoner, Jan Kaczmarczyk, Colantonio Simona, Robin A. Felder, Richard G. Saul, King C Chan, Josip Blonder
Publikováno v:
Oncotarget
Background: Lung cancer is the leading cause of cancer-related deaths in the USA and worldwide. Yet, about 95% of new drug candidates validated in preclinical phase eventually fail in clinical trials. Such a high attrition rate is attributed mostly t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1006c8eb7d3140ea7925addca94b3fac
https://doi.org/10.21203/rs.3.rs-72194/v1
https://doi.org/10.21203/rs.3.rs-72194/v1
Autor:
Thomas E Smith, Ryan M. Van Wagoner, Nader N. El-Chaar, Ashlee R. Venancio, Philip J. Moos, Andrea Bild, Zhenyu Lu, Stephen R. Piccolo, Gajendra Shreshtha, Mary Kay Harper, Chris M. Ireland
BackgroundBreast cancer is a heterogeneous disease. Genomic studies have revealed five different intrinsic subtypes - Luminal A, Luminal B, HER2-enriched, Claudin-low, and Basal-like. Patients diagnosed with Basal-like or Claudin-low breast cancer (B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c4d815f91398922ea13f666525e16eb
https://doi.org/10.1101/2020.04.17.047555
https://doi.org/10.1101/2020.04.17.047555